LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced the initiation of a dose escalation study with its oncology drug candidate tamibarotene combined with TRISENOX® (arsenic trioxide) injection (marketed by Cephalon, Inc.) in patients with relapsed acute promyelocytic leukemia (APL). There are two primary trial objectives. The first is to determine the safety and preliminary efficacy of combining tamibarotene with arsenic trioxide as a treatment for relapsed or refractory APL. The second objective is to determine the appropriate dose for future clinical trials in which CytRx would test the utility of the tamibarotene/arsenic trioxide combination as a first-line treatment for subjects who prefer not to be exposed to anthracyclines. The dose escalation study is being financed jointly by CytRx and Cephalon.
